Cantor Fitzgerald Maintains Overweight on Lumos Pharma, Lowers Price Target to $10
Portfolio Pulse from jenniferd'souza@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has maintained an Overweight rating on Lumos Pharma (NASDAQ:LUMO) but lowered the price target from $14 to $10.
August 15, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Lumos Pharma but lowered the price target from $14 to $10.
The lowering of the price target by Cantor Fitzgerald could potentially lead to a decrease in Lumos Pharma's stock price in the short term. Investors may interpret this as a sign of decreased confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100